Arutselvan Natarajan1, Sanjiv Sam Gambhir. 1. Department of Radiology, Molecular Imaging Program at Stanford (MIPS), James H. Clark Center, 318 Campus Drive, E153, Stanford, CA, 94305, USA.
Abstract
PURPOSE: We evaluated the dosimetry of [(89)Zr]rituximab, an anti-CD20 immunoPET tracer to image B cell non-Hodgkin's lymphoma (NHL) using a humanized transgenic mouse model that expresses human CD20 transgenic mice (huCD20TM). PROCEDURES: Rituximab was conjugated to desferrioxamine (Df) for radiolabeling of Zirconium-89. [(89)Zr]rituximab (2.8 ± 0.2 MBq) was tail vein-injected into huCD20T mice. Positron emission tomography (PET)/CT imaging was performed on the two groups of mice (blocking = 2 mg/kg pre-dose of rituximab and non-blocking; n = 5) at eight time points (1, 4, 24, 48, 72, 96, 120, and 168 h) post injection. RESULTS: The novel [(89)Zr]rituximab PET tracer had good immunoreactivity, was stable in human serum, and was able to specifically target human CD20 in mice. The human equivalents of highest dose (mean ± SD) organs with and without pre-dose are liver (345 ± 284 μSv/MBq) and spleen (1165 ± 149 μSv/MBq), respectively. CONCLUSIONS: Dosimetry of the human patient whole-body dose was found to be 145 MBq per annum, and the patient dose-limiting organ will be the liver (with rituximab pre-dose blocking) and spleen for non-blocking. The [(89)Zr]rituximab (t½ = 78.4 h) imaging of B cell NHL patients could permit the observation of targeting lesions in NHL patients over an extended period due to longer half-life as compared to the [(64)Cu] rituximab (t½ = 12.7 h).
PURPOSE: We evaluated the dosimetry of [(89)Zr]rituximab, an anti-CD20 immunoPET tracer to image B cell non-Hodgkin's lymphoma (NHL) using a humanized transgenicmouse model that expresses humanCD20transgenic mice (huCD20TM). PROCEDURES: Rituximab was conjugated to desferrioxamine (Df) for radiolabeling of Zirconium-89. [(89)Zr]rituximab (2.8 ± 0.2 MBq) was tail vein-injected into huCD20T mice. Positron emission tomography (PET)/CT imaging was performed on the two groups of mice (blocking = 2 mg/kg pre-dose of rituximab and non-blocking; n = 5) at eight time points (1, 4, 24, 48, 72, 96, 120, and 168 h) post injection. RESULTS: The novel [(89)Zr]rituximab PET tracer had good immunoreactivity, was stable in human serum, and was able to specifically target humanCD20 in mice. The human equivalents of highest dose (mean ± SD) organs with and without pre-dose are liver (345 ± 284 μSv/MBq) and spleen (1165 ± 149 μSv/MBq), respectively. CONCLUSIONS: Dosimetry of the humanpatient whole-body dose was found to be 145 MBq per annum, and the patient dose-limiting organ will be the liver (with rituximab pre-dose blocking) and spleen for non-blocking. The [(89)Zr]rituximab (t½ = 78.4 h) imaging of B cell NHL patients could permit the observation of targeting lesions in NHL patients over an extended period due to longer half-life as compared to the [(64)Cu] rituximab (t½ = 12.7 h).
Authors: Lars R Perk; Otto J Visser; M Stigter-van Walsum; Maria J W D Vosjan; Gerard W M Visser; Josée M Zijlstra; Peter C Huijgens; Guus A M S van Dongen Journal: Eur J Nucl Med Mol Imaging Date: 2006-07-11 Impact factor: 9.236
Authors: Arutselvan Natarajan; Gayatri Gowrishankar; Carsten H Nielsen; Sen Wang; Andrei Iagaru; Michael L Goris; Sanjiv Sam Gambhir Journal: Mol Imaging Biol Date: 2012-10 Impact factor: 3.488
Authors: Gregory A Wiseman; Bryan Leigh; William D Erwin; Dominick Lamonica; Ellen Kornmehl; Stewart M Spies; Daniel H S Silverman; Thomas E Witzig; Richard B Sparks; Christine A White Journal: Cancer Date: 2002-02-15 Impact factor: 6.860
Authors: Saiyada N F Rizvi; Otto J Visser; Maria J W D Vosjan; Arthur van Lingen; Otto S Hoekstra; Josée M Zijlstra; Peter C Huijgens; Guus A M S van Dongen; Mark Lubberink Journal: Eur J Nucl Med Mol Imaging Date: 2012-01-05 Impact factor: 9.236
Authors: Arutselvan Natarajan; Aaron T Mayer; Robert E Reeves; Claude M Nagamine; Sanjiv Sam Gambhir Journal: Mol Imaging Biol Date: 2017-12 Impact factor: 3.488
Authors: Kirstin A Zettlitz; Richard Tavaré; Scott M Knowles; Kristopher K Steward; John M Timmerman; Anna M Wu Journal: Clin Cancer Res Date: 2017-09-19 Impact factor: 12.531
Authors: Kornelis S M van der Geest; Maria Sandovici; Pieter H Nienhuis; Riemer H J A Slart; Peter Heeringa; Elisabeth Brouwer; William F Jiemy Journal: Front Med (Lausanne) Date: 2022-06-06
Authors: Yvonne W S Jauw; Josée M Zijlstra; Daphne de Jong; Danielle J Vugts; Sonja Zweegman; Otto S Hoekstra; Guus A M S van Dongen; Marc C Huisman Journal: PLoS One Date: 2017-01-06 Impact factor: 3.240